Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh School of Medicine, Pittsburgh, USA.
Laryngoscope. 2012 Jul;122(7):1512-7. doi: 10.1002/lary.23341. Epub 2012 Jun 8.
OBJECTIVES/HYPOTHESIS: To estimate the distribution of head and neck squamous cell carcinoma (HNSCC) recurrence after definitive chemoradiation therapy (CRT) among patients who underwent 18F-fluorodeoxyglucose positron-emission tomography and computed tomography (PET/CT) surveillance.
Retrospective review.
HNSCC patients who underwent definitive CRT from 2001 to 2008 were evaluated for recurrence with serial PET/CT. Patients were excluded if they were previously treated for recurrent disease, were treated with surgery as the primary therapeutic modality, or had inadequate clinical follow-up. Recurrence was defined by histopathologic evidence of tumor.
Three hundred eighty-eight patients were studied. Patients in whom recurrence was not detected were followed clinically and radiographically for a median of 27 months. Tumor recurrence was detected in 110 patients. For 37 patients, recurrence was heralded by clinical signs. Among the 73 asymptomatic patients who had a confirmed recurrence, disease was detected by PET/CT between 2 and 43 months, median of 6 months. Forty-five percent of observed asymptomatic recurrences were detected during the first 6 months of surveillance (95% confidence interval [CI], 34%-57%), 79% within the first 12 months (95% CI, 68%-88%), 95% within the first 24 months (95% CI, 87%-98%), and 100% within the first 48 months (95% CI, 95%-100%).
Among HNSCC patients followed with PET/CT surveillance, 95% of observed asymptomatic recurrences were detected within 24 months after completing CRT. For patients without clinical signs of recurrence, routine PET/CT surveillance beyond the first 24 months may be of limited value and may not be cost effective.
目的/假设:评估在接受 18F-氟代脱氧葡萄糖正电子发射断层扫描和计算机断层扫描(PET/CT)监测的患者中,接受根治性放化疗(CRT)后的头颈部鳞状细胞癌(HNSCC)复发的分布。
回顾性研究。
对 2001 年至 2008 年期间接受根治性 CRT 的 HNSCC 患者进行了连续 PET/CT 复发评估。如果患者之前接受过复发性疾病的治疗、主要治疗方式为手术或临床随访不足,则排除在外。复发定义为肿瘤的组织病理学证据。
共研究了 388 例患者。未发现复发的患者在临床上和影像学上随访中位数为 27 个月。110 例患者检测到肿瘤复发。在 37 例有临床症状的患者中,复发由临床症状提示。在 73 例无症状且确诊复发的患者中,PET/CT 在 2 至 43 个月(中位数为 6 个月)后检测到疾病。在观察到的无症状复发中,45%在监测的前 6 个月内(95%置信区间[CI],34%-57%),79%在第 12 个月内(95%CI,68%-88%),95%在第 24 个月内(95%CI,87%-98%),100%在第 48 个月内(95%CI,95%-100%)。
在接受 PET/CT 监测的 HNSCC 患者中,95%的观察到的无症状复发在 CRT 完成后 24 个月内被发现。对于没有复发临床迹象的患者,在第 24 个月后进行常规 PET/CT 监测可能价值有限,并且可能不符合成本效益。